Advertisement

Evidence-Based Practice: Temozolomide Beyond Glioblastoma

  • Jason Chua
  • Elizabeth Nafziger
  • Denise LeungEmail author
Neuro-oncology (Y Umemura, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Neuro-oncology

Abstract

Purpose of Review

Temozolomide is a first-line treatment for newly diagnosed glioblastoma. In this review, we will examine the use of temozolomide in other contexts for treating gliomas, including recurrent glioblastoma, glioblastoma in the elderly, diffuse low- and high-grade gliomas, non-diffuse gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma.

Recent Findings

Temozolomide improved survival in older patients with glioblastoma, anaplastic gliomas regardless of 1p/19q deletion status, and progressive ependymomas. Temozolomide afforded less toxicity and comparable efficacy to radiation in high-risk low-grade gliomas and to platinum-based chemotherapy in pediatric high-grade gliomas.

Summary

The success of temozolomide in promoting survival has expanded beyond glioblastoma to benefit patients with non-glioblastoma tumors. Identifying practical biomarkers for predicting temozolomide susceptibility, and establishing complementary agents for chemosensitizing tumors to temozolomide, will be key next steps for future success.

Keywords

Temozolomide Low grade glioma GBM in the elderly Ependymoma Pilocytic astrocytoma Pleomorphic xanthoastrocytoma DIPG Bevacizumab 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J med. 2005;352:987–96.  https://doi.org/10.1056/NEJMoa043330 This study demonstrated, both clinically and statistically, significant survival benefit with the addition of temozolomide to radiotherapy for glioblastoma, without significant toxicity. This has now become the standard of care following maximal safe surgical resection.CrossRefPubMedGoogle Scholar
  2. 2.
    Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2013:Cd007415.  https://doi.org/10.1002/14651858.CD007415.pub2.
  3. 3.
    Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23:35–61.CrossRefGoogle Scholar
  4. 4.
    Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5:144–51.CrossRefGoogle Scholar
  5. 5.
    Brindley CJ, Antoniw P, Newlands ES. Plasma and tissue disposition of mitozolomide in mice. Br J Cancer. 1986;53:91–7.CrossRefGoogle Scholar
  6. 6.
    Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neuro-Oncol. 2011;103:585–93.  https://doi.org/10.1007/s11060-010-0423-2.CrossRefGoogle Scholar
  7. 7.
    Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer. 2006;95:1155–60.  https://doi.org/10.1038/sj.bjc.6603376.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, et al. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro-Oncology. 2014;16:1255–62.  https://doi.org/10.1093/neuonc/nou044.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology. 2002;4:39–43.  https://doi.org/10.1093/neuonc/4.1.39.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro-Oncology. 2010;12:289–96.  https://doi.org/10.1093/neuonc/nop030.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, et al. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro-Oncology. 2013;15:930–5.  https://doi.org/10.1093/neuonc/not040.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology. 2013;15:242–50.  https://doi.org/10.1093/neuonc/nos295.CrossRefPubMedGoogle Scholar
  13. 13.
    Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28:2051–7.  https://doi.org/10.1200/jco.2009.26.5520.CrossRefPubMedGoogle Scholar
  14. 14.
    • Weller M, Tabatabai G, Kastner B, Felsberg J, Steinbach JP, Wick A, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21:2057–64.  https://doi.org/10.1158/1078-0432.Ccr-14-2737 This study aimed to identify how dose-intense regimens of temozolomide may be beneficial in treatment of recurrent glioblastoma. There was no major difference in efficacy between one week on/one week off temozolomide compared with three weeks on/one week off. It did, however, indicate that temozolomide rechallenge should not be considered for patients with an unmethylated MGMT promoter status, although it is a viable option for methylated-MGMT tumors, as the median time to treatment failure, progression-free survival, and overall survival were longer versus unmethylated tumors.CrossRefPubMedGoogle Scholar
  15. 15.
    Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357–61.  https://doi.org/10.1200/jco.2007.10.7722.CrossRefPubMedGoogle Scholar
  16. 16.
    Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012;118:1302–12.  https://doi.org/10.1002/cncr.26381.CrossRefPubMedGoogle Scholar
  17. 17.
    Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010;21:1723–7.  https://doi.org/10.1093/annonc/mdp591.CrossRefPubMedGoogle Scholar
  18. 18.
    Ironside S, Das S, Sahgal A, Moroney C, Mainprize T, Perry JR. Optimal therapies for newly diagnosed elderly patients with glioblastoma. Curr Treat Options in Oncol. 2017;18:66.  https://doi.org/10.1007/s11864-017-0508-7.CrossRefGoogle Scholar
  19. 19.
    Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916–26.  https://doi.org/10.1016/s1470-2045(12)70265-6.CrossRefPubMedGoogle Scholar
  20. 20.
    Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707–15.  https://doi.org/10.1016/s1470-2045(12)70164-x.CrossRefPubMedGoogle Scholar
  21. 21.
    Gallego Perez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29:3050–5.  https://doi.org/10.1200/jco.2011.34.8086.CrossRefPubMedGoogle Scholar
  22. 22.
    • Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017;376:1027–37.  https://doi.org/10.1056/NEJMoa1611977 Since previous trials implementing Stupp protocol largely excluded patients > 70 years of age, there were few data about the benefit of temozolomide for older patients with glioblastoma. This study was notable for showing that addition of temozolomide does provide survival benefit in elderly patients, even if overall prognosis is poorer compared to younger patients.CrossRefPubMedGoogle Scholar
  23. 23.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016(131):803–20.  https://doi.org/10.1007/s00401-016-1545-1.
  24. 24.
    Drappatz J, Lieberman F. Chemotherapy of oligodendrogliomas. Prog Neurol Surg. 2018;31:152–61.  https://doi.org/10.1159/000467376.CrossRefPubMedGoogle Scholar
  25. 25.
    van den Bent MJ, Smits M, Kros JM, Chang SM. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol. 2017;35:2394–401.  https://doi.org/10.1200/jco.2017.72.6737.CrossRefPubMedGoogle Scholar
  26. 26.
    Lecavalier-Barsoum M, Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev. 2014:Cd007104.  https://doi.org/10.1002/14651858.CD007104.pub2.
  27. 27.
    van den Bent MJ, Chang SM. Grade II and III oligodendroglioma and astrocytoma. Neurol Clin. 2018;36:467–84.  https://doi.org/10.1016/j.ncl.2018.04.005.CrossRefPubMedGoogle Scholar
  28. 28.
    Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J 3rd, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers (Version I.2018). Accessed November 1, 2018.Google Scholar
  29. 29.
    Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus Procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374:1344–55.  https://doi.org/10.1056/NEJMoa1500925.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    • Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17:1521–32.  https://doi.org/10.1016/s1470-2045(16)30313-8 This was the first study to randomly assign patients with low-grade glioma and at least one high-risk feature to radiotherapy alone or temozolomide chemotherapy alone. Although there was no improvement in progression-free survival with chemotherapy alone, temozolomide may prevent or delay patients from the side effects of radiation by using a similarly effective therapy. Subgroup analysis suggested that IDH mutant, non-co-deleted tumors treated with radiotherapy had a longer progression-free survival than those treated with temozolomide (such that temozolomide treatment alone might be deleterious).CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424. Int J Radiat Oncol Biol Phys. 2015;91:497–504.  https://doi.org/10.1016/j.ijrobp.2014.11.012.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Fisher B, Zhang P, Macdonald D, Chakravarti A, Lesser G, Fox S, et al. ACTR-2. NRG Oncology/RTOG 0424: Long term results of a phase II study of temozolomide-based chemoradiotherapy regimen for high risk low-grade gliomas. Neuro-Oncology. 2018;20.  https://doi.org/10.1093/neuonc/noy148.039.
  33. 33.
    • Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial. JAMA Oncol. 2018;4:1405–9.  https://doi.org/10.1001/jamaoncol.2018.1977 This was the first study to demonstrate MGMT methylation as an independent prognostic factor in low-grade glioma treated with temozolomide and radiotherapy.CrossRefPubMedGoogle Scholar
  34. 34.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874–80.  https://doi.org/10.1200/jco.2009.23.6497.CrossRefPubMedGoogle Scholar
  35. 35.
    • Izquierdo C, Alentorn A, Idbaih A, Simo M, Kaloshi G, Ricard D, et al. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. J Neurooncol. 2018;136:533–9.  https://doi.org/10.1007/s11060-017-2677-4 This group examined the growth kinetics of co-deleted low-grade gliomas who were treated with upfront temozolomide, finding that most tumors resumed their growth within 3 years of treatment. They argued that volumetric analysis to identify early tumor progression can prevent unnecessary exposure to temozolomide, which could put patients at risk for malignant progression (based on mutational analyses proposed that TMZ exposure can lead to acquisition of a hypermutation, leading to progression). CrossRefPubMedGoogle Scholar
  36. 36.
    • van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390:1645–53.  https://doi.org/10.1016/s0140-6736(17)31442-3 Before this trial, there had not been a well-designed study supporting adjuvant temozolomide for grade II and III gliomas. This study demonstrated that the less-chemosensitive 1p/19q non-co-deleted anaplastic gliomas still derived benefit from temozolomide therapy. It showed prolonged overall survival with 12 cycles of adjuvant temozolomide in addition to radiotherapy. The role of concurrent temozolomide therapy is not yet established. CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Massimino M, Spreafico F, Biassoni V, Simonetti F, Riva D, Trecate G, et al. Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neuro-Oncol. 2008;87:355–61.  https://doi.org/10.1007/s11060-008-9525-5.CrossRefGoogle Scholar
  38. 38.
    van Zanten SEM V, Lane A, Heymans MW, Baugh J, Chaney B, Hoffman LM, et al. External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the international DIPG registry and the SIOPE DIPG registry. J Neurooncol. 2017;134:231–40.  https://doi.org/10.1007/s11060-017-2514-9.CrossRefGoogle Scholar
  39. 39.
    Rizzo D, Scalzone M, Ruggiero A, Maurizi P, Attina G, Mastrangelo S, et al. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? J Chemother. 2015;27:106–10.  https://doi.org/10.1179/1973947814y.0000000228.CrossRefPubMedGoogle Scholar
  40. 40.
    Hassan H, Pinches A, Picton SV, Phillips RS. Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis. J Neuro-Oncol. 2017;135:13–20.  https://doi.org/10.1007/s11060-017-2546-1.CrossRefGoogle Scholar
  41. 41.
    Bailey S, Howman A, Wheatley K, Wherton D, Boota N, Pizer B, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy—results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer. 2013;49:3856–62.  https://doi.org/10.1016/j.ejca.2013.08.006.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the children's oncology group. Neuro-Oncology. 2011;13:410–6.  https://doi.org/10.1093/neuonc/noq205.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Sirachainan N, Pakakasama S, Visudithbhan A, Chiamchanya S, Tuntiyatorn L, Dhanachai M, et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro-Oncology. 2008;10:577–82.  https://doi.org/10.1215/15228517-2008-025.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Warren KE. Beyond the blood:brain barrier: the importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors including diffuse intrinsic pontine glioma. Front Oncol. 2018;8:239.  https://doi.org/10.3389/fonc.2018.00239.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    • Seidel C, von Bueren AO, Bojko S, Hoffmann M, Pietsch T, Gielen GH, et al. Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen: acute toxicity in pediatric high-grade glioma patients. Strahlenther Onkol. 2018:194:215–224. Doi: https://doi.org/10.1007/s00066-017-1218-6. This study identified that cisplatin-based chemotherapy demonstrated increased toxicity (mostly hematologic), with more interruptions of treatment, in comparison with temozolomide in pediatric high-grade gliomas. While the efficacy of chemotherapies for pediatric high-grade glioma are similar (and poor), the authors argued for temozolomide use with radiotherapy because of relatively lower toxicity.
  46. 46.
    • Flannery PC, JA DS, Amani V, Venkataraman S, Lemma RT, Prince EW, et al. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep. 2018;39:455–64.  https://doi.org/10.3892/or.2017.6122 AZD2014 is a MTOR complex 1 and 2 inhibitor that was studied in three patient-derived DIPG cell lines. Its use potentiated greatly increased antitumor efficacy, via increased inhibition of cell self-renewal. It also demonstrated a synergistic relationship with dose-dependent radiotherapy, and also with other chemotherapies.CrossRefPubMedGoogle Scholar
  47. 47.
    Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014;20:1394–6.  https://doi.org/10.1038/nm.3716.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med. 2018;24:572–9.  https://doi.org/10.1038/s41591-018-0006-x.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Reyes-Botero G, Giry M, Mokhtari K, Labussiere M, Idbaih A, Delattre JY, et al. Molecular analysis of diffuse intrinsic brainstem gliomas in adults. J Neuro-Oncol. 2014;116:405–11.  https://doi.org/10.1007/s11060-013-1312-2.CrossRefGoogle Scholar
  50. 50.
    Reyes-Botero G, Mokhtari K, Martin-Duverneuil N, Delattre JY, Laigle-Donadey F. Adult brainstem gliomas. Oncologist. 2012;17:388–97.  https://doi.org/10.1634/theoncologist.2011-0335.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Salmaggi A, Fariselli L, Milanesi I, Lamperti E, Silvani A, Bizzi A, et al. Natural history and management of brainstem gliomas in adults. A retrospective Italian study. J Neurol. 2008;255:171–7.  https://doi.org/10.1007/s00415-008-0589-0.CrossRefPubMedGoogle Scholar
  52. 52.
    Babu R, Kranz PG, Karikari IO, Friedman AH, Adamson C. Clinical characteristics and treatment of malignant brainstem gliomas in elderly patients. J Clin Neurosci. 2013;20:1382–6.  https://doi.org/10.1016/j.jocn.2012.12.011.CrossRefPubMedGoogle Scholar
  53. 53.
    Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, et al. Adult brainstem gliomas: correlation of clinical and molecular features. J Neurol Sci. 2015;353:92–7.  https://doi.org/10.1016/j.jns.2015.04.014.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Freyschlag CF, Tuettenberg J, Lohr F, Thome C, Schmieder K, Seiz M. Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. Anticancer Res. 2011;31:1023–5.PubMedGoogle Scholar
  55. 55.
    Gramatzki D, Roth P, Felsberg J, Hofer S, Rushing EJ, Hentschel B, et al. Chemotherapy for intracranial ependymoma in adults. BMC Cancer. 2016;16:287.  https://doi.org/10.1186/s12885-016-2323-0.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    • Ruda R, Bosa C, Magistrello M, Franchino F, Pellerino A, Fiano V, et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro Oncol. 2016;18:261–8.  https://doi.org/10.1093/neuonc/nov167 Before this study, there were few data to guide the addition of further chemotherapy to recurrent or progressive ependymomas despite initial resection and radiation. Although the efficacy of temozolomide among these select patients was variable, favorable results in chemotherapy-naïve patients suggested a role for temozolomide after failure of first-line treatments. Intriguingly, these benefits occurred independent of MGMT methylation status.CrossRefPubMedGoogle Scholar
  57. 57.
    Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 4):iv1–63.  https://doi.org/10.1093/neuonc/nou223.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Bond KM, Hughes JD, Porter AL, Orina J, Fang S, Parney IF. Adult pilocytic astrocytoma: an institutional series and systematic literature review for extent of resection and recurrence. World Neurosurg. 2018;110:276–83.  https://doi.org/10.1016/j.wneu.2017.11.102.CrossRefPubMedGoogle Scholar
  59. 59.
    Dirven CM, Mooij JJ, Molenaar WM. Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature. Childs Nerv Syst. 1997;13:17–23.  https://doi.org/10.1007/s003810050033.CrossRefPubMedGoogle Scholar
  60. 60.
    Krieger MD, Gonzalez-Gomez I, Levy ML, McComb JG. Recurrence patterns and anaplastic change in a long-term study of pilocytic astrocytomas. Pediatr Neurosurg. 1997;27:1–11.  https://doi.org/10.1159/000121218.CrossRefPubMedGoogle Scholar
  61. 61.
    Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA, et al. Temozolomide in children with progressive low-grade glioma. Neuro-Oncology. 2007;9:161–8.  https://doi.org/10.1215/15228517-2006-030.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer. 2007;49:808–11.  https://doi.org/10.1002/pbc.21270.CrossRefPubMedGoogle Scholar
  63. 63.
    Katayama K, Asano K, Shimamura N, Ogasawara Y, Naraoka M, Ohkuma H, et al. Case of pleomorphic xanthoastrocytoma with anaplastic features in the pineal gland. Brain Tumor Pathol. 2013;30:242–6.  https://doi.org/10.1007/s10014-013-0137-1.CrossRefPubMedGoogle Scholar
  64. 64.
    Suzuki Y, Akiyama Y, Kimura Y, Sugita S, Hasegawa T, Mikuni N. Pleomorphic xanthoastrocytoma with anaplastic features in the tectal region in a young adult patient: a case report. World Neurosurg. 2016;94(580):e11–5.  https://doi.org/10.1016/j.wneu.2016.07.110.CrossRefGoogle Scholar
  65. 65.
    Zhu M, Zhang C, Zhao K, Wang L, Sun J, Feng Y, et al. Anaplastic pleomorphic xanthoastrocytoma with disseminated growth pattern at the time of diagnosis as well as after treatment: case report and review of literature. Chinese Neurosurgical Journal. 2017;3:22.  https://doi.org/10.1186/s41016-017-0087-2.CrossRefGoogle Scholar
  66. 66.
    Thompson EM, Landi D, Ashley D, Keir ST, Bigner D. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. J Neuro-Oncol. 2018;140:261–8.  https://doi.org/10.1007/s11060-018-2975-5.CrossRefGoogle Scholar
  67. 67.
    Precision Medicine in Cancer Treatment. https://www.cancer.gov/about-cancer/treatment/types/precision-medicine. Accessed November 1, 2018.
  68. 68.
    Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. BRAF inhibition in BRAF(V600)-mutant gliomas: results From the VE-BASKET study. J Clin Oncol. 2018;Jco2018789990.  https://doi.org/10.1200/jco.2018.78.9990.
  69. 69.
    Roskoski R Jr. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacol Res. 2018;135:239–58.  https://doi.org/10.1016/j.phrs.2018.08.013.CrossRefPubMedGoogle Scholar
  70. 70.
    Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: a review. Pharmacol Ther. 2018;185:122–34.  https://doi.org/10.1016/j.pharmthera.2017.12.002.CrossRefPubMedGoogle Scholar
  71. 71.
    Pianko MJ, Liu Y, Bagchi S, Lesokhin AM. Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig. 2017;4:32.  https://doi.org/10.21037/sci.2017.03.04.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8:539–51.  https://doi.org/10.1016/j.apsb.2018.03.001.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:775–88.  https://doi.org/10.1007/s00401-015-1410-7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Neurology, University of MichiganAnn ArborUSA

Personalised recommendations